Another study, enrolling 162 NSCLC patients with KRAS mutations, showed a trend which ICI offered a better response rate and PFS when the PD-L1 was higher, though the results were not statistically significant.[11] In addition, co-mutations may predict the different clinical benefits of ICI. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.